Impact of Increased Activated Protein-C Resistance, Decreased Antithrombin III Activity and Hypocomplementemia on the Gestational Outcomes of Pregnancies with MTHFR Polymorphisms

Abstract

Objective To evaluate the impact of increased Activated Protein C (APC) resistance, decreased antithrombin III activity and hypocomplementemia on the pregnancy outcomes of the patients with methylentetrahydrofolate reductase (MTHFR) polymorphisms.

Methods This study was composed of 83 pregnancies with MTHFR polymorphisms. Increased APC resistance, decreased antithrombin III activity and hypocomplementemia were accepted as risk factors for poor gestational outcome.

Results Having at least one risk factor resulted in significantly higher rates of “APGAR score of<7” at the first ten minutes (p=0.009). Composite adverse outcome rate was also higher in patients with at least one of the defined risk factors despite lack of statistical significance (p=0.241). Rate of newborn with an “APGAR score of<7” at first ten minutes was significantly higher at patients with hypocomplementemia (p=0.03).

Conclusion Hypocomplementemia is a risk factor for poor gestational outcome in pregnancies with MTHFR polymorphisms.

Key words

pregnancy - mthfr polymorphisms - Activated Protein C resistance - Antithrombin III activity - hypocomplementemia

• References

• 1 Hulthén Varli I, Petersson K, Kublickas M. et al. Both acute and chronic placental inflammation are overrepresented in term stillbirths: a case-control study. Infect Dis Obstet Gynecol 2012; 2012: 293867
• 2 Tannetta D, Sargent I. Placental disease and the maternal syndrome of preeclampsia: missing links?. Curr Hypertens Rep 2013; 15: 590-599
• 3 Seremak-Mrozikiewicz A, Drews K, Kurzawinska G. et al. The significance of 1793G>A polymorphism in MTHFR gene in women with first trimester recurrent miscarriages. Neuro Endocrinol Lett 2010; 31: 717
• 4 Lai WKC, Kan MY. Homocysteine-induced endothelial dysfunction. Ann of Nutr Metab 2015; 67: 1-12
• 5 Sazci A, Ergul E, Kaya G. et al. Genotype and allele frequencies of the polymorphic methylenetetrahydrofolate reductase gene in Turkey. Cell Biochem Funct 2005; 23: 51-54
• 6 Konwar C, Price EM, Wang LQ. et al. DNA methylation profiling of acute chorioamnionitis-associated placentas and fetal membranes: insights into epigenetic variation in spontaneous preterm births. Epigenetics Chromatin 2018; 11: 63
• 7 Alfirevic Z, Mousa HA, Martlew V. et al. Postnatal screening for thrombophilia in women with severe pregnancy complications. Obstet Gynecol 2001; 97: 753-759
• 8 Stonek F, Hafner E, Metzenbauer M. et al. Carriage of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism does not influence the first and second trimester uterine artery Doppler flow. Eur J Obstet Gynecol Reprod Biol 2008; 140: 178-182
• 9 Ogueh O, Chen M, Spurll G. et al. Outcome of pregnancy in women with hereditary thrombophilia. Int J Gynecol Obstet 2001; 74: 247-253
• 10 Lund M, Nielsen H, Hviid T. et al. Hereditary thrombophilia and recurrent pregnancy loss: a retrospective cohort study of pregnancy outcome and obstetric complications. Hum Reprod 2010; 25: 2978-2984
• 11 Refaei M, Xing L, Lim W. et al. Management of venous thromboembolism in patients with hereditary antithrombin deficiency and pregnancy: case report and review of the literature. Case Rep Hematol 2017; 2017: 9261351
• 12 Kayıran SM, Zülfikar B. Cerebral venous thrombosis in a patient with heterozygous methylenetetrahydrofolate reductase (C677T) polymorphism. Şişli Etfal Hastan 43: 131-133
• 13 Rodger MA, Betancourt MT, Clark P. et al. The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010; 7: e1000292
• 14 Beksaç K, Örgül G, Çağan M. et al. Retrospective evaluation of pregnant women with celiac disease. J Turk Ger Gynecol Assoc 2017; 18: 56-59
• 15 Tanacan A, Beksac MS, Orgul G. et al. Impact of extractable nuclear antigen, anti-double stranded DNA, antiphospholipid antibody, and anticardiolipin antibody positivity on obstetrical complications and pregnancy outcomes. Hum Antibodies 2019; 27: 135-141
• 16 Orgul G, Aktoz F, Beksac MS. Behcet’s disease and pregnancy: what to expect?. J Obstet Gynaecol 2018; 38: 185-188
• 17 Erenel H, Davutoğlu EA, Özel A. et al. Pregnancy and Behcet’s Disease: Obstetric outcomes of 33 patients. Şişli Etfal Hastan 2017; 51: 318-321
• 18 Micheloud D, Sarmiento E, Teijeiro R. et al. Hypocomplementemia in the absence of autoantibodies in women with recurrent pregnancy loss. Allergol immunopathol 2007; 35: 90-94
• 19 Kobayashi N, Yamada H, Kishida T. et al. Hypocomplementemia correlates with intrauterine growth retardation in systemic lupus erythematosus. Am J Reprod Immunol 1999; 42: 153-159
• 20 Beksaç MS, Aydın E, Tuğral M. et al. An obstetrics index for the assessment of risk levels of “high risk pregnancy” groups. Gynecol Obstet Reprod Med 2016; 21: 10-13
• 21 Fadiloglu E, Unal C, Beksac MS. Management and the pregnancy outcomes of patients positive for anti-parietal cell antibody. Hum Antibodies 2019; 27: 111-116
• 22 Beksaç MS, Unal C, Tanacan A. et al Chorionic villus sampling experience of a reference perinatal medicine center. Ann Hum Genet 2020; 84: 229-234 Epub 2019 Dec 4
• 23 Frosst P, Blom H, Milos R. et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113
• 24 Machnik G, Zapała M, Pelc E. et al. A new and improved method based on polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for the determination of A1298C mutation in the methylenetetrahydrofolate reductase (MTHFR) gene. Ann Clin Lab Sci 2013; 43: 436-440
• 25 Jääskeläinen E, Keski-Nisula L, Toivonen S. et al. MTHFR C677T polymorphism is not associated with placental abruption or preeclampsia in Finnish women. Hypertens Pregnancy 2006; 25: 73-80
• 26 Nurk E, Tell GS, Refsum H. et al. Associations between maternal methylenetetrahydrofolate reductase polymorphisms and adverse outcomes of pregnancy: the Hordaland Homocysteine Study. Am J Med 2004; 117: 26-31
• 27 Wu X, Zhao L, Zhu H. et al. Association between the MTHFR C677T polymorphism and recurrent pregnancy loss: a meta-analysis. Genet Test Mol Biomarkers 2012; 16: 806-811
• 28 Hague WM. Homocysteine and pregnancy. Best Pract Res Clin Obstet Gynaecol 2003; 17: 459-469
• 29 Vollset SE, Refsum H, Irgens LM. et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr 2000; 71: 962-968
• 30 Walker MC, Smith GN, Perkins SL. et al. Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol 1999; 180: 660-664
• 31 Weisberg IS, Jacques PF, Selhub J. et al. The 1298A→ C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 2001; 156: 409-415
• 32 Brenner B, Mandel H, Lanir N. et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997; 97: 551-554
• 33 Nurk E, Tell G, Refsum H. et al. Factor V Leiden, pregnancy complications and adverse outcomes: the Hordaland Homocysteine Study. QJM 2006; 99: 289-298
• 34 Raskob GE, Silverstein R, Bratzler DW. et al. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med 2010; 38: S502-S509
• 35 Sabadell J, Casellas M, Alijotas-Reig J. et al. Inherited antithrombin deficiency and pregnancy: maternal and fetal outcomes. Eur J Obstet Gynecol Reprod Biol 2010; 149: 47-51
• 36 Fadiloglu E, Unal C, Tanacan A. et al. Effect of hypocomplementemia on perinatal outcomes of pregnancies with autoimmune disorders. Hum Antibodies 2020; 28: 179-184
• 37 Aye IL, Lager S, Ramirez VI. et al. Increasing maternal body mass index is associated with systemic inflammation in the mother and the activation of distinct placental inflammatory pathways. Biol Reprod 2014; 90: 129